<DOC>
	<DOCNO>NCT01497574</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare within-subject variability pharmacokinetic profile insulin detemir insulin glargine child adolescent type 1 diabetes .</brief_summary>
	<brief_title>Within-subject Variability Insulin Detemir Children Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes least 12 month Body mass index ( BMI ) child ( 6 12 year ) : 1520 kg/m^2 ( inclusive ) Body mass index ( BMI ) adolescent ( 13 17 year ) : 1825 kg/m^2 ( inclusive ) HbA1c ( glycosylated haemoglobin ) 11.0 % accord central laboratory result Current treatment insulin least twice daily Any significant disease endocrine , hepatic , renal , cardiac , neurological , malignant , pancreatic disease diabetes Receipt investigational product within last four week Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>